← Back to patent-cliff list
布比卡因脂质体
Tier C — Watch / tradeLiposomal bupivacaine
Pacira Pharmaceuticals Inc
Originator
2011
First approval
-
Expiry (public)
$0.6B ▲
Peak sales
化学药
Type
Targets：SCNA
Brand：Exparel liposomal、Exparel
Indications (approved)：疼痛、术后疼痛
Regional status
US
批准上市
2011-10-28
EU
批准上市
2020-11-16
China
批准上市
2022-11-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Liposomal bupivacaine?
Approved indications include: 疼痛, 术后疼痛.
When does the Liposomal bupivacaine patent expire?
No public expiry year is available for Liposomal bupivacaine yet; this page updates once verified.
How do I get a quote for Liposomal bupivacaine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24